Foote J, Schachman H K
J Mol Biol. 1985 Nov 5;186(1):175-84. doi: 10.1016/0022-2836(85)90267-0.
The active sites of aspartate transcarbamoylase from Escherichia coli were titrated by measuring the decrease in the enzyme-catalyzed arsenolysis of N-carbamoyl-L-aspartate caused by the addition of the tight-binding inhibitor, N-phosphonacetyl-L-aspartate. Because the enzyme is a poor catalyst for this non-physiological reaction, high concentrations are required for the assays (more than 1000-fold the dissociation constant of the reversibly bound inhibitor) and, therefore, virtually all of the bisubstrate analog is bound. From the endpoint of the titration, 5.7 active sites were calculated, in excellent agreement with the number, six, based on the structure of the enzyme. Simple inhibition was observed only when the molar ratio of inhibitor to enzyme exceeded five; under these conditions, as shown in earlier physical chemical studies, the R-conformational state of the enzyme is the sole or predominant species. At low ratios of inhibitor to enzyme, the addition of inhibitor caused an increase in activity which is attributable to the conversion of the enzyme from the low-activity T-state to the much more active R-state. Comparison of the linear increase in activity as a function of inhibitor concentration at the low molar ratio (0.01, i.e. 1 inhibitor/600 active sites) with the activity lost at the high ratio provided a direct value for the mean number of active sites converted from the T-state to the R-state as a result of the binding of one bisubstrate analog to an enzyme molecule. This number was four with Mg X ATP or carbamoyl phosphate present and 4.7 for the enzyme in the presence of Mg X PPi, values approaching or identical to the theoretical maximum, 4.7, for a concerted transition with all of the active sites of the molecule changing from the T- to R-state upon the formation of a binary complex of hexameric enzyme with a single inhibitor. With the enzyme in the absence of effectors or with Mg X CTP present, the titrations showed that an average of two and one sites, respectively, of 4.7 possible, changed conformation upon ligand binding. These results were interpreted as a manifestation of an equilibrium between a sub-population of T- and R-state enzyme complexes containing one bound inhibitor molecule. The R-state species would represent 40% of the population for aspartate transcarbamoylase in the absence of extraneous ligands.(ABSTRACT TRUNCATED AT 400 WORDS)
通过测量添加紧密结合抑制剂N-膦酰乙酰-L-天冬氨酸后,大肠杆菌天冬氨酸转氨甲酰酶催化的N-氨甲酰-L-天冬氨酸的砷解反应速率降低,对该酶的活性位点进行了滴定。由于该酶对这种非生理反应的催化能力较差,测定需要高浓度的底物(比可逆结合抑制剂的解离常数高1000倍以上),因此,几乎所有的双底物类似物都被结合。根据滴定终点,计算出有5.7个活性位点,与基于酶结构的六个活性位点的数量非常吻合。只有当抑制剂与酶的摩尔比超过5时,才观察到简单抑制作用;在这些条件下,如早期物理化学研究所示,酶的R构象状态是唯一的或主要的状态。在抑制剂与酶的低比例下,添加抑制剂会导致活性增加,这归因于酶从低活性的T态转变为活性更高的R态。将低摩尔比(0.01,即1个抑制剂/600个活性位点)下活性随抑制剂浓度的线性增加与高比例下丧失的活性进行比较,可直接得出由于一个双底物类似物与一个酶分子结合,从T态转变为R态的活性位点平均数。在存在MgXATP或氨甲酰磷酸的情况下,这个数字是4,在存在MgXPPi的情况下,对于该酶来说是4.7,这些值接近或等同于理论最大值4.7,即对于六聚体酶与单个抑制剂形成二元复合物时,分子中所有活性位点从T态转变为R态的协同转变。在没有效应物或存在MgXCTP的情况下,滴定表明,在可能的4.7个位点中,平均分别有2个和1个位点在配体结合时发生构象变化。这些结果被解释为含有一个结合抑制剂分子的T态和R态酶复合物亚群之间平衡的表现。在没有外来配体的情况下,天冬氨酸转氨甲酰酶的R态物种占总数的40%。(摘要截短于400字)